Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Encino. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in Encino at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)
Sponsor: Karyopharm Therapeutics Inc
Check if you qualify for this myelofibrosis clinical trial in Encino, CA
If you're searching for myelofibrosis treatment options in Encino, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Encino research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.